Hemangiomas are common benign vascular tumors distinctive for their perinatal presentation, rapid growth during the first year of life and subsequent slowly involution. Many evidences suggest that hemangiomas are angiogenesis dependent entity. Research also indicated that the endothelium of hemangioma shared molecular phenotype with blood cells. LMO2 is a transcriptional regulator that play an important role in angiogenesis, hematopoiesis and oncogenesis of hematological tumor. It is logical to postulate that LMO2 may play a role in the pathogenesis, proliferating and involution of hemangioma. Therapies directed against LMO2 have potential importance for treatment of hemangioma because of hemangioma's limited localization and the fact that LMO2-associated protein complexes could regulate angiogenesis.